Aimmune Therapeutics, Inc. (NASDAQ:AIMT) CEO Sells $30,280.96 in Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) CEO Stephen George Dilly sold 1,154 shares of the business’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $26.24, for a total transaction of $30,280.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Stephen George Dilly also recently made the following trade(s):

  • On Friday, October 6th, Stephen George Dilly sold 4,047 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $26.31, for a total transaction of $106,476.57.
  • On Thursday, October 5th, Stephen George Dilly sold 14,689 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $26.24, for a total transaction of $385,439.36.
  • On Wednesday, October 4th, Stephen George Dilly sold 80,110 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $26.23, for a total transaction of $2,101,285.30.
  • On Monday, September 25th, Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $25.01, for a total transaction of $2,501,000.00.
  • On Wednesday, July 26th, Stephen George Dilly sold 50,000 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $21.46, for a total transaction of $1,073,000.00.

Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) traded down 2.77% during midday trading on Friday, hitting $29.88. 780,743 shares of the stock were exchanged. The company’s market cap is $1.51 billion. Aimmune Therapeutics, Inc. has a 12-month low of $14.87 and a 12-month high of $37.50. The firm has a 50-day moving average price of $25.40 and a 200-day moving average price of $25.40.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). On average, equities analysts predict that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/28/aimmune-therapeutics-inc-aimt-ceo-stephen-george-dilly-sells-1154-shares.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC boosted its holdings in shares of Aimmune Therapeutics by 10.1% in the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 499 shares during the period. Legal & General Group Plc boosted its holdings in shares of Aimmune Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 1,634 shares during the period. Voya Investment Management LLC boosted its holdings in shares of Aimmune Therapeutics by 31.2% in the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 3,757 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Aimmune Therapeutics in the 2nd quarter valued at about $333,000. Finally, American International Group Inc. boosted its holdings in shares of Aimmune Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 1,070 shares during the period. 72.91% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently commented on AIMT shares. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, July 27th. Wedbush reissued an “ourperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research report on Monday, August 14th. Credit Suisse Group boosted their price target on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. Finally, BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $51.00.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply